To investigate the interactions of POLθ inhibition with the immune microenvironment in HR-deficient cancers, we first determined the effect of POLθ inhibition on PD-L1 expression in two different BRCA-deficient cancer cell lines. This evidence concerns the gene CD274 and cancer.